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Constanze Schmidt: Professor Hubbard, you are very strongly involved in the 100 000 genomes project-can you tell us something about the point of the project?
Tim Hubbard: The project was really set up in 2012 to see-because genome sequencing had got so much cheaper-there was a government report saying that it was time to start thinking about doing that in the health service.
So that's what the project is: to see if you can use whole-genome sequencing directly in a health service for clinical care and whether there's enough value to implementing it. And, in fact, for rare diseases, we've decided there's enough value and it will be folded into direct care this year.
Constanze Schmidt: Cardiovascular Research recently published a special issue of GWAS (Genome-wide association studies) in cardiovascular research medicine. How do you think genome information will influence the health care of patients in the future?
For example, will patient biopsies be comprehensively analysed with regards to their genome, epigenome, and proteome?
Tim Hubbard: I think at the start, the kind of thing we're doing in Genomics England-collecting the whole genome sequence-once you've got that whole genome, you can analyse it in lots of different ways. Although right now we're only doing rare disease and cancer analysis, because that's all we really understand enough, people are already talking about calculating polygenic risk scores from that whole genome. I think if you're going to go down the biopsy route with epigenetics, that's somewhere in the future-but it may add enough value. We have some samples like that which we're collecting for research purposes rather than direct care. At the moment, direct care is based on whole-genome sequencing. Tim Hubbard: People worry about this. You know, the National Health Service (NHS) in the UK has 1.4 million people in the system. They're all going to need to know something about genomics-but they don't need to become bioinformaticians. The idea is the reports that are generated by automatic processing will be enough to be like clinical decision support guidelines for them. They'll apply their clinical knowledge, but they'll need to know a background in genomics. So we do need some training, and we have quite a lot of training structures in place now as we're implementing genome medicine in the NHS.
Constanze Schmidt: How should academic teaching account for current developments in the field of genome research and bioinformatics?
Tim Hubbard: That's also happening. You have to re-train the existing doctors but you also have to change the training of new doctors. At King's College, we've re-designed our degree for medics-training for medics-to incorporate more genetics and bioinformatics as part of that. So that kind of work is getting folded into the curriculums now. It needs to. Everybody's got to be a data scientist to some extent-particularly if they're doing basic research.
Constanze Schmidt: Thank you, Professor Hubbard.
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